促销时间表 Biohaven Pharmaceutical Holding Company Ltd.
关于公司
Biohaven Pharmaceutical Holding Company Ltd., биофармацевтическая компания на клинической стадии, разрабатывает продукты-кандидаты на поздних стадиях, нацеленные на неврологические заболевания и редкие расстройства в Соединенных Штатах. Его продукты на клинической стадии включают Римегепант, продукт, который прошел III фазу испытаний для лечения острых состояний и профилактики мигрени; Вазегепант, завершивший испытание фазы 2> F3 по неотложному лечению и профилактике мигрени; и Трорилузол, завершивший фазу рандомизации II \ u002FIII и продолжающийся расширенное исследование атаксии.
更多详情P/S | 13.12 |
---|---|
P/BV | 1.15 |
EV/EBITDA | 0.6611 |
EBITDA | -0.4791 |
Цена ао | 51.27 |
Сайт | http://www.biohavenpharma.com |
Число акций ао | 0.0712 млрд |
Выручка | 0.4625 |
Див.доход ао | 0 |
ISIN | VGG111961055 |
Валюта | usd |
IPO date | 2022-09-23 |
Sector | Health Care |
Industry | Biotechnology |
Валюта отчета | usd |
每日价格变化: | +4.8% (51.27) |
---|---|
每周价格变化: | +12.81% (47.63) |
每月价格变化: | +50.42% (35.72) |
3个月内价格变化: | +41.06% (38.09) |
六个月内的价格变化: | +19.99% (44.78) |
每年价格变化: | +93.97% (27.7) |
年初以来价格变化: | +81.15% (29.66) |
|
低估
|
效率
|
|||||||||||||||||||||||||||||||||||||
股息
|
责任
|
成长冲动
|
交易日期 | 披露日期 | 内幕 | 类型 | 价格 | 体积 | 数量 | 分享最多, % | 之后分享, % | 文档 |
---|---|---|---|---|---|---|---|---|---|
19.08.2022 | 22.08.2022 | Bailey Gregory Director |
购买 | 148.04 | 5 625 520 | 38000 | 0 | 0.06 | 关联 |
07.01.2022 | 07.01.2022 | Coric Vlad Chief Executive Officer |
购买 | 129.48 | 1 294 800 | 10000 | 0 | 0.02 | 关联 |
07.01.2022 | 07.01.2022 | JONES WILLIAM A JR CCO-Migraine & Common Disease |
购买 | 129.48 | 485 550 | 3750 | 0 | 0.01 | 关联 |
07.01.2022 | 07.01.2022 | Stock Elyse Chief Medical Officer |
购买 | 129.48 | 129 480 | 1000 | 0 | 0 | 关联 |
07.01.2022 | 07.01.2022 | Stock Elyse Chief Medical Officer |
购买 | 129.48 | 420 810 | 3250 | 0 | 0 | 关联 |
07.01.2022 | 07.01.2022 | Engelhart James Strategic Advisor |
购买 | 129.48 | 420 810 | 3250 | 0 | 0 | 关联 |
06.01.2022 | 07.01.2022 | Coric Vlad Chief Executive Officer |
购买 | 129.48 | 1 618 500 | 12500 | 0 | 0.02 | 关联 |
06.01.2022 | 07.01.2022 | JONES WILLIAM A JR CCO-Migraine & Common Disease |
购买 | 129.48 | 647 400 | 5000 | 0 | 0.01 | 关联 |
06.01.2022 | 07.01.2022 | Stock Elyse Chief Medical Officer |
购买 | 129.48 | 161 850 | 1250 | 0 | 0 | 关联 |
06.01.2022 | 07.01.2022 | Stock Elyse Chief Medical Officer |
购买 | 129.48 | 485 550 | 3750 | 0 | 0.01 | 关联 |
06.01.2022 | 07.01.2022 | Engelhart James Strategic Advisor |
购买 | 129.48 | 485 550 | 3750 | 0 | 0.01 | 关联 |
10.12.2021 | 10.12.2021 | Engelhart James Chief Financial Officer |
销售 | 102.55 | 3 589 250 | 35000 | 0 | -0.05 | 关联 |
10.12.2021 | 10.12.2021 | Engelhart James Chief Financial Officer |
购买 | 99.73 | 3 490 550 | 35000 | 0 | 0.05 | 关联 |
06.01.2021 | 08.01.2021 | Coric Vlad Chief Executive Officer |
购买 | 85.72 | 1 071 500 | 12500 | 0 | 0.02 | 关联 |
06.01.2021 | 08.01.2021 | Conway Charles Chief Scientific Officer |
购买 | 85.72 | 321 450 | 3750 | 0 | 0.01 | 关联 |
06.01.2021 | 08.01.2021 | Engelhart James Chief Financial Officer |
购买 | 85.72 | 321 450 | 3750 | 0 | 0.01 | 关联 |
25.11.2020 | 27.11.2020 | Conway Charles Chief Scientific Officer |
购买 | 91.36 | 274 080 | 3000 | 0 | 0.01 | 关联 |
25.11.2020 | 27.11.2020 | Coric Vlad Chief Executive Officer |
购买 | 91.36 | 1 000 390 | 10950 | 0 | 0.02 | 关联 |
25.11.2020 | 27.11.2020 | Engelhart James Chief Financial Officer |
购买 | 91.36 | 338 032 | 3700 | 0 | 0.01 | 关联 |
25.11.2020 | 27.11.2020 | Gentile Kimberly SVP, Clinical Operations |
购买 | 91.36 | 342 600 | 3750 | 0 | 0.01 | 关联 |
25.11.2020 | 27.11.2020 | JONES WILLIAM A JR CCO-Migraine & Common Disease |
购买 | 91.36 | 274 080 | 3000 | 0 | 0.01 | 关联 |
25.11.2020 | 27.11.2020 | Stock Elyse Chief Medical Officer |
购买 | 91.36 | 308 340 | 3375 | 0 | 0.01 | 关联 |
25.11.2020 | 27.11.2020 | Tilton John Chief Commercial Officer |
购买 | 91.36 | 114 200 | 1250 | 0 | 0 | 关联 |
机构 | 体积 | 分享, % |
---|---|---|
Stifel Financial Corporation | 6225811 | 7.63 |
Janus Henderson Group PLC | 5901343 | 7.23 |
Blackrock Inc. | 5762738 | 7.06 |
Suvretta Capital Management, LLC | 4572836 | 5.6 |
State Street Corporation | 3870839 | 4.74 |
Price (T.Rowe) Associates Inc | 3134323 | 3.84 |
RP Management, LLC | 2936507 | 3.6 |
Point72 Asset Management, L.P. | 2483567 | 3.04 |
Adage Capital Partners GP L.L.C. | 2020644 | 2.48 |
FMR, LLC | 1928992 | 2.36 |
ETF | 分享, % | 本年盈利能力, % | 股息, % |
---|---|---|---|
PSYK ETF | 7.04 | ||
iShares ESG Aware MSCI USA Small-Cap ETF | 0.08795 | 31.110458284371 | 1.49366 |
iShares Neuroscience and Healthcare ETF | 4.14142 | 19.720292847757 | 0.03 |
iShares Morningstar Small-Cap ETF | 0.06651 | 30.095066471445 | 1.60498 |
iShares Morningstar Small-Cap Growth ETF | 0.13211 | 33.628071953382 | 0.72598 |
iShares Russell 2000 Growth ETF | 0.22426 | 38.042556988 | 0.6026 |
iShares Russell 3000 ETF | 0.00529 | 31.230028873917 | 1.43482 |
iShares Morningstar Small-Cap ETF | 0.06651 | 391.25300933451 | 1.60498 |
iShares Morningstar Small-Cap Growth ETF | 0.13211 | 682.83677107207 | 0.72598 |
导师 | 职称 | 支付 | 出生年份 |
---|---|---|---|
Ms. Kimberly Gentile | Senior Vice President of Clinical Operations | 858.65k | 1966 (58 年) |
Mr. Clifford Bechtold M.S. | President, GM of Biohaven Ireland & Chief Compliance Officer | N/A | |
Mr. George C. Clark | VP & Chief Accounting Officer | N/A | 1984 (40 年) |
Dr. Vladimir Coric M.D. | Chairman & CEO | 1.96M | 1971 (53 年) |
Mr. Matthew Buten | Chief Financial Officer | 1.05M | 1961 (63 年) |
Dr. Bruce D. Car DACVP, Ph.D. | Chief Scientific Officer | 883.03k | 1962 (62 年) |
Ms. Jennifer Porcelli | Vice President of Investor Relations | N/A | |
Mr. John Tilton | Chief Commercial Officer of Rare Diseases | N/A | 1968 (56 年) |
Ms. Deb Young | Director of Regulatory Affairs & Operations | N/A | |
Mr. Warren Volles J.D. | General Counsel & Chief Legal Officer | N/A |
网站: http://www.biohavenpharma.com